Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp185 | Pituitary & endocrine Tumours | ECE2017

Localization of benign insulinomas using glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT and PET/CT and MRI in a prospective clinical study

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Reubi Jean Claude , Gloor Beat , Wild Damian , Christ Emanuel

Purpose: We aim at prospectively comparing the detection rate of GLP1-R PET/CT vs GLP1-R SPECT/CT vs standardized contrast enhanced 3T-MRI in patients with suspected insulinoma.Methods: 40 patients with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled.3T-MRI was performed. Afterwards patients received SPECT/CT after injection of 111In-DOTA-exendin-4 and PET/CT after injection of <sup...

ea0041ep590 | Endocrine tumours and neoplasia | ECE2016

Localization of benign insulinomas using glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT and PET/CT in a prospective clinical study

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Reubi Jean Claude , Gloor Beat , Wild Damian , Christ Emanuel

Purpose: The aim of our study is to compare the detection rate of GLP-1R PET/CT and GLP-1R SPECT/CT in patients with a biochemically proven endogenous hyperinsulinemic hypoglycemia. Preliminary results of an ongoing study are reported.Methods: Thirty-three patients (25 females, 8 males, age range 18–80 years, mean 49 years) with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled (ClinicalTrials.gov, NCT02127541).<...

ea0041ep607 | Endocrine tumours and neoplasia | ECE2016

Glucagon-like-1 Receptor imaging specifically localizes insulinomas in patients with Multiple Endocrine Neoplasia Type 1 (MEN-1)

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Pattou Francois , Grossmann Ashley , Chanson Philippe , Reubi Jean Claude , Gloor Beat , Wild Damian , Christ Emanuel

Introduction: Surgery is often the only treatment option that can effectively treat patients with insulinoma in MEN-1. However, the surgical intervention should be limited as surgery can not cure patients with MEN-1. It is, therefore, mandatory to correctly localize insulin secreting tumors from other neuroendocrine tumors.Materials and Methods: In this report we include 6 patients with proven endogenous hyperinsulinemic hypoglycemia and neuroglycopenia ...

ea0037gp.28.02 | Endocrine tumours and neoplasia – NETS | ECE2015

Localisation of insulinoma: comparison of glucagon-like peptide 1 receptor SPECT/CT, PET/CT, and MRI: preliminary results of a prospective clinical study

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Reubi Jean Claude , Gloor Beat , Fischli Stefan , Wild Damian , Christ Emanuel

Purpose: We aim at prospectively comparing the detection rate of glucagon-like peptide 1 receptor (GLP1R) PET/CT vs GLP1R SPECT/CT vs standardised contrast enhanced 3T MRI in patients with endogenous hyperinsulinaemic hypoglycaemia.Methods: 14 patients with neuroglycopenic symptoms due to endogenous hyperinsulinaemic hypoglycaemia were already enrolled (mean age 56 years, ten females and four males). A standardized contrast enhanced 3T MRI was performed....

ea0090p656 | Endocrine-related Cancer | ECE2023

Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms – a feasibility study

Hubalewska-Dydejczyk Alicja , Decristoforo Clemens , Kolenc Petra , Mikolajczak Renata , Ležaić Luka , Suden Andrej , Garnuszek Piotr , Simoncic Urban , Virgolini Irene , Trofimiuk-Muldner Malgorzata , Opalinska Marta , Rangger Christine , Glowa Boguslaw , Skorkiewicz Konrad , Fani Melpomeni , Sowa Staszczak Anna , Janota Barbara , Kroselj Marko , Zaletel Katja , Von Guggenberg Elisabeth

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...

ea0099oc7.3 | Oral Communications 7: Endocrine-related Cancer | ECE2024

How close we are to optimise the assessment of SSTR status in NEN with a radiolabelled SSTR antagonist-final results of the TECANT clinical trial: Novel 99mTc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms

Hubalewska-Dydejczyk Alicja , Ležaić Luka , Decristoforo Clemens , Mikolajczak Renata , Virgolini Irene , Kolenc Petra , Suden Andrej , Simoncic Urban , Opalinska Marta , Trofimiuk-Muldner Malgorzata , Garnuszek Piotr , di Santo Gianpaolo , Novak Doroteja , Rangger Christine , Kroselj Marko , Skorkiewicz Konrad , Fani Melpomeni , Janota Barbara , Glowa Boguslaw , Sawicka Agnieszka

Introduction/Aim: Within the past two decades, the imaging and treatment of patients with neuroendocrine neoplasms (NEN) has been redefined by the successful introduction of radiolabelled somatostatin receptor (SSTR)-agonists targeting SSTR-subtype2 (SSTR2) overexpressed in NEN cells. Reliable assessment of the SSTR status of the primary focus/metastasis in different NEN locations is a cornerstone of NEN management and enables a personalised/precise therapeutic appr...